logo
ScreenersREIT EarningsREIT SectorsIndustriesMarketplace
Logo

Arcus Biosciences, Inc.

RCUS

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimabā€¦ read more

Healthcare

Biotechnology

7 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$25.56

Price

+5.27%

$1.28

$24.28

Previous Close

$24.10

Open

Premium

52w Discount
Market Cap

$2.760b

Mid

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-500.0%

EBITDA Margin

-519.2%

Net Profit Margin

-373.1%

Free Cash Flow Margin
Revenue

$240m

-7.0%

1y CAGR

+39.3%

3y CAGR

+11.8%

5y CAGR
Earnings

-$349m

-23.3%

1y CAGR

-10.2%

3y CAGR

-158.6%

5y CAGR
EPS

-$3.40

-8.3%

1y CAGR

+1.4%

3y CAGR

-154.6%

5y CAGR
Book Value

$436m

$974m

Assets

$538m

Liabilities

$111m

Debt
Debt to Assets

11.4%

-0.3x

Debt to EBITDA
Free Cash Flow

-$464m

-163.6%

1y CAGR

-97.8%

3y CAGR

-10.1%

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.